Market Overview

Dermira to Present at the 18th Annual Needham Healthcare Conference

Share:

Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to
bringing biotech ingenuity to medical dermatology by delivering
differentiated, new therapies to the millions of patients living with
chronic skin conditions, today announced that company management will
participate in a fireside chat at the 18th Annual Needham
Healthcare Conference on Wednesday, April 10, 2019 at 12:50 p.m. ET.

A live audio webcast and archive of the presentation will be available
at http://investor.dermira.com.

About Dermira

Dermira is a biopharmaceutical company dedicated to bringing biotech
ingenuity to medical dermatology by delivering differentiated, new
therapies to the millions of patients living with chronic skin
conditions. Dermira is committed to understanding the needs of both
patients and physicians and using its insight to identify, develop and
commercialize leading-edge medical dermatology products. The company's
approved treatment, QBREXZA™ (glycopyrronium) cloth, is indicated for
pediatric and adult patients (ages 9 and older) with primary axillary
hyperhidrosis (excessive underarm sweating). Please see the QBREXZA prescribing
information
. Dermira is also evaluating lebrikizumab for the
treatment of moderate-to-severe atopic dermatitis (a severe form of
eczema) and plans to initiate a Phase 3 clinical development program by
the end of 2019; and has early-stage research and development programs
in other areas of dermatology. Dermira is headquartered in Menlo Park,
Calif. For more information, please visit http://www.dermira.com.
Follow Dermira on TwitterLinkedIn and Instagram.

In addition to filings with the Securities and Exchange
Commission (SEC), press releases, public conference calls and
webcasts, Dermira uses its website (www.dermira.com),
LinkedIn page (https://www.linkedin.com/company/dermira-inc-),
corporate Instagram account (https://www.instagram.com/dermira_inc/)
and corporate Twitter account (@DermiraInc) as channels of distribution
of information about its company, product candidates, planned financial
and other announcements, attendance at upcoming investor and industry
conferences and other matters. Such information may be deemed material
information and Dermira may use these channels to comply with its
disclosure obligations under Regulation FD. Therefore, investors should
monitor Dermira's website, LinkedIn page, Instagram and Twitter accounts
in addition to following its SEC filings, news releases, public
conference calls and webcasts.

Forward-Looking Statements

The information in this news release contains forward-looking statements
and information within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended, which are subject to the "safe harbor" created by
those sections. This news release contains forward-looking statements
that involve substantial risks and uncertainties, including statements
with respect to Dermira's goal of bringing biotech ingenuity to medical
dermatology by delivering differentiated, new therapies to the millions
of patients living with chronic skin conditions and Dermira's plans to
initiate a Phase 3 development program for lebrikizumab by the end of
2019. These statements deal with future events and involve known and
unknown risks, uncertainties and other factors that may cause actual
results, performance or achievements to be materially different from the
information expressed or implied by these forward-looking statements.
Factors that could cause actual results to differ materially include
risks and uncertainties such as those relating to Dermira's dependence
on third-party clinical research organizations, manufacturers, suppliers
and distributors; the design and implementation of Dermira's clinical
trials; the outcomes of future meetings with regulatory agencies;
Dermira's ability to attract and retain key employees; Dermira's ability
to manage the growth and complexity of its organization; Dermira's
ability to maintain, protect and enhance its intellectual property; and
Dermira's ability to continue to stay in compliance with its material
contractual obligations, applicable laws and regulations. You should
refer to the section entitled "Risk Factors" set forth in Dermira's
Annual Report on Form 10-K, Dermira's Quarterly Reports on Form 10-Q and
other filings Dermira makes with the SEC from time to time for a
discussion of important factors that may cause actual results to differ
materially from those expressed or implied by Dermira's forward-looking
statements. Furthermore, such forward-looking statements speak only as
of the date of this news release. Dermira undertakes no obligation to
publicly update any forward-looking statements or reasons why actual
results might differ, whether as a result of new information, future
events or otherwise, except as required by law.

View Comments and Join the Discussion!